AVLSA
Atlas Venture Life Science Advisors Portfolio holdings
AUM
$662M
This Quarter Return
-4.67%
1 Year Return
+6.63%
3 Year Return
+286.7%
5 Year Return
–
10 Year Return
–
AUM
$739M
AUM Growth
+$739M
(-11%)
Cap. Flow
-$6.1M
Cap. Flow
% of AUM
-0.83%
Top 10 Holdings %
Top 10 Hldgs %
94.94%
Holding
17
New
–
Increased
6
Reduced
1
Closed
1
Top Buys
| 1 |
Day One Biopharmaceuticals
DAWN
|
$536K |
| 2 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$438K |
| 3 |
Dianthus Therapeutics
DNTH
|
$250K |
| 4 |
Dyne Therapeutics
DYN
|
$184K |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$20.5K |
Top Sells
| 1 |
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
|
$3.79M |
| 2 |
Kymera Therapeutics
KYMR
|
$3.75M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Kymera Therapeutics
KYMR
$2.95B
| $174M | 23.5% | 5,858,262 -126,474 | -2% | -$3.75M |
|
|
2
Dyne Therapeutics
DYN
$1.92B
| $114M | 15.42% | 9,885,449 +15,966 | +0.2% | +$184K |
|
|
3
Day One Biopharmaceuticals
DAWN
$769M
| $102M | 13.77% | 7,608,394 +40,077 | +0.5% | +$536K |
|
4
Disc Medicine
IRON
$2.07B
| $73.4M | 9.93% | 3,461,784 | – | – |
|
|
VIGL
5
DELISTED
Vigil Neuroscience
VIGL
| $57.1M | 7.74% | 5,836,874 | – | – |
|
|
THRD
6
DELISTED
Third Harmonic Bio
THRD
| $44.9M | 6.08% | 10,907,859 | – | – |
|
|
JBIO
7
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $41.1M | 5.57% | 2,039,249 +21,728 | +1% | +$438K |
|
8
Replimune Group
REPL
$422M
| $37.1M | 5.02% | 2,098,300 | – | – |
|
9
Generation Bio
GBIO
$40.4M
| $35.6M | 4.82% | 8,279,484 +608 | +0% | +$2.61K |
|
10
Akero Therapeutics
AKRO
$3.74B
| $22.7M | 3.08% | 594,251 | – | – |
|
|
IMA
11
ImageneBio, Inc. Common Stock
IMA
$150M
| $17.3M | 2.34% | 5,018,178 | – | – |
|
12
Xilio Therapeutics
XLO
$36.3M
| $8.75M | 1.18% | 2,759,344 | – | – |
|
|
TECX
13
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $4.54M | 0.61% | 4,541,381 +20,518 | +0.5% | +$20.5K |
|
|
14
Dianthus Therapeutics
DNTH
$759M
| $3.01M | 0.41% | 3,791,698 +315,162 | +9% | +$250K |
|
15
Viridian Therapeutics
VRDN
$1.5B
| $2.29M | 0.31% | 90,072 | – | – |
|
16
Spero Therapeutics
SPRO
$116M
| $1.5M | 0.2% | 1,031,160 | – | – |
|
|
FSTX
17
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| – | – | -599,524 | Closed | -$3.79M |
|